LILY34 Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$135.49 |
| 52 Week High | US$134.81 |
| 52 Week Low | US$67.25 |
| Beta | 0.37 |
| 1 Month Change | 3.60% |
| 3 Month Change | 27.08% |
| 1 Year Change | 98.20% |
| 3 Year Change | 296.94% |
| 5 Year Change | 786.87% |
| Change since IPO | 4,485.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| LILY34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 6.5% | 4.4% | 1.2% |
| 1Y | 98.2% | -13.4% | 17.9% |
Return vs Industry: LILY34 exceeded the BR Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: LILY34 exceeded the BR Market which returned 17.9% over the past year.
Price Volatility
| LILY34 volatility | |
|---|---|
| LILY34 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: LILY34 has not had significant price volatility in the past 3 months.
Volatility Over Time: LILY34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LILY34 fundamental statistics | |
|---|---|
| Market cap | R$3.45t |
| Earnings (TTM) | R$27.21b |
| Revenue (TTM) | R$177.19b |
134.3x
P/E Ratio20.6x
P/S RatioIs LILY34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LILY34 income statement (TTM) | |
|---|---|
| Revenue | US$34.12b |
| Cost of Revenue | US$7.08b |
| Gross Profit | US$27.04b |
| Other Expenses | US$21.80b |
| Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 79.25% |
| Net Profit Margin | 15.36% |
| Debt/Equity Ratio | 233.4% |
How did LILY34 perform over the long term?
See historical performance and comparison